Cat No. 59-P86

BEZ235 (NPV-BEZ235)

5 mg

For research purposes only

BEZ235 is a dual inhibitor of phosphatidylinositol 3-kinase (P13K)and the downstream mammalian target of rapamycin (mTOR) by binding to the ATP-binding cleft of these enzymes. It specifically blocks the dysfunctional activation of the P13K pathway and induce G(1) arrest. BEZ235 has been shown to inhibit VEGF induced cell proliferation and survival *in vitro* and VEGF induced angiogenesis *in vivo*. It has also been shown to inhibit the growth of human cancer in animal models.

TECHNICAL INFORMATION



Other Names: 4-[2,3-dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo[4, 5-c]quinolin-1-yl]-α,α-dimethyl-benzeneacetonitrile , NPV-BEZ235

Chemical Formula: $C_{30}H_{23}N_5O$

CAS Number: 915019-65-7

Molecular Weight: 469.54

Purity: >98%

Appearance: a crystalline solid

Solubility: DMSO

STORAGE AND HANDLING

Storage: Store at 4°C and protected from light. Following reconstitution, store aliquots at -20°C.

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

PRODUCT USE

Soluble in DMSO up to 100mM. If precipitate is observed, vortex for 5 minutes.

REFERENCES

1. Maira et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 7(7):1851-63.
2. Schnell et al. (2008) Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res. 68(16):6598-607.
3. Cho et al. (2010) The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res. 16 (14):3628-38.